Catalyst Event

Sanofi (SNY) · Other

From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)

3/18/2026, 12:00:00 AM

OtherSentiment: Positive

The US FDA granted Breakthrough Therapy designation to Sanofi's venglustat for the treatment of neurological manifestations of type 3 Gaucher disease (GD3).

Korean Translation

미국 FDA, 사노피의 벤글루스타트를 제3형 고셔병(GD3)의 신경학적 증상 치료제로 혁신치료제 지정함.

Related Recent Events

View Full Timeline